Injectable formulation of disodium 1-[2-(carboxylato)pyrrolidin-1-yl] diazen-1-ium-1,2-diolate (PROLI/NO), an ultrafast nitric oxide donor prodrug

Journal of Pharmaceutical Sciences

Volumn 95, Issue 1, 2006, Pages 108-115

  Waterhouse, David J ^a   Saavedra, Joseph E ^b   Davies, Keith M ^c   Citro, Michael L ^b   Xu, Xia ^d   Powell, Douglas A ^a   Grimes, George J ^e   Potti, Gopal K ^e   Keefer, Larry K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c GEORGE MASON UNIVERSITY   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Analytical chemistry; Chemical stability; Chirality; Kinetics; Lyophilization; Nitric oxide; Prodrugs; Solvate; Stabilization; Targeted drug delivery

Indexed keywords

BICARBONATE; CARBONIC ACID; CARBOXYLIC ACID DERIVATIVE; DISODIUM 1 [2 (CARBOXYLATO)PYRROLIDIN 1 YL]DIAZEN 1 IUM 1,2 DIOLATE; MANNITOL; N NITROSOPROLINE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRITE; PRODRUG; PROLINE; PYRROLIDINE DERIVATIVE; SODIUM DERIVATIVE; SODIUM HYDROXIDE; UNCLASSIFIED DRUG; DRUG DERIVATIVE; NITROGEN OXIDE; PROLINE NITRIC OXIDE; PROLINE-NITRIC OXIDE;

ARTICLE; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; FREEZE DRYING; INJECTION; PH; ULTRAFILTRATION; CHEMISTRY; HYDROLYSIS; INTRAVENOUS DRUG ADMINISTRATION;

DRUG COMPOUNDING; DRUG STORAGE; HYDROLYSIS; INJECTIONS, INTRAVENOUS; NITRIC OXIDE; NITRIC OXIDE DONORS; NITROGEN OXIDES; PRODRUGS; PROLINE;

EID: 33645236065     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20486     Document Type: Article

References (31)

1. Saavedra JE, Southan GJ, Davies KM, Lundell A, Markou C, Hanson SR, Adrie C, Hurford WE, Zapol WM, Keefer LK. 1996. Localizing antithrombotic and vasodilatory activity with a novel, ultrafast nitric oxide donor. J Med Chem 39:4361-4365.
2. Adrie C, Hirani WM, Holzmann A, Keefer L, Zapol WM, Hurford WE. 1998. Selective pulmonary vasodilation by intravenous infusion of an ultra-short half-life nucleophile/nitric oxide adduct. Anesthesiology 88:190-195.
3. Pluta RM, Oldfield EH, Boock RJ. 1997. Reversal and prevention of cerebral vasospasm by intracarotid infusions of nitric oxide donors in a primate model of subarachnoid hemorrhage. J Neurosurg 87:746-751.
4. Chen C, Hanson SR, Keefer LK, Saavedra JE, Davies KM, Hutsell TC, Hughes JD, Ku DN, Lumsden AB. 1997. Boundary layer infusion of nitric oxide reduces early smooth muscle cell proliferation in the endarterectomized canine artery. J Surg Res 67:26-32.
5. Davies KM, Wink DA, Saavedra JE, Keefer LK. 2001. Chemistry of the diazeniumdiolates 2. Kinetics and mechanism of dissociation to nitric oxide in aqueous solution. J Am Chem Soc 123:5473-5481.
6. Lijinsky W, Keefer L, Loo J. 1970. The preparation and properties of some nitrosamino acids. Tetrahedron 26:5137-5153.
7. Nims RW, Cook JC, Krishna MC, Christodoulou D, Poore CMB, Miles AM, Grisham MB, Wink DA. 1996. Colorimetric assays for nitric oxide and nitrogen oxide species formed from nitric oxide stock solutions and donor compounds. Methods Enzymol 268:93-105.
8. Chinard FP. 1952. Photometric estimation of proline and ornithine. J Biol Chem 199:91-95.
9. Analysis of pentaerythritol tetranitrate on the CE-440 elemental analyzer Rev. 1 http://www.eai1. com/tn211.htm.
10. Keefer LK, Nims RW, Davies KM, Wink DA. 1996. "NONOates" (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: Convenient nitric oxide dosage forms. Methods Enzymol 268:281-293.
11. Conover WJ. 1980. Practical nonparametric statistics. New York: John Wiley & Sons.
12. Efron B. 1982. The jackknife, the bootstrap, and other resampling plans. Bristol, England: Arrow-smith.
13. Tuteja N, Chandra M, Tuteja R, Misra MK. 2004. Nitric oxide as a unique bioactive signaling messenger in physiology and pathophysiology. J Biomed Biotechnol 2004:227-237.
14. Cosby K, Partovi KS, Crawford JH, Patel RP, Reiter CD, Martyr S, Yang BK, Waclawiw MA, Zalos G, Xu X, Huang KT, Shields H, Kim-Shapiro DB, Schechter AN, Cannon RO, III, Gladwin MT. 2003. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med 9:1498-1505.
15. Ohshima H, Bartsch H. 1981. Quantitative estimation of endogenous nitrosation in humans by monitoring n-nitrosoproline excreted in the urine. Cancer Res 41:3658-3662.
16. Bartsch H. 2002. Hunting for electrophiles that harm human DNA: Frits Cobels Award Lecture. Mutagenesis 17:281-287.
17. Gaffield W, Lundin RE, Keefer LK. 1981. Chiroptical properties of N-nitrosopyrrolidines and N-nitrosamino acids: Implications for the nitrosamine sector rule. Tetrahedron 37:1861-1869.
18. Cherkin A, Davis JL, Garman MW. 1978. D-proline: Stereospecificity and sodium chloride dependence of lethal convulsant activity in the chick. Pharmacol Biochem Behav 8:623-625.
19. Nadler JV, Wang A, Hakim A. 1988. Toxicity of L-proline toward rat hippocampal neurons. Brain Res 456:168-172.
20. Kampel D, Kupferschmidt R, Lubec G. 1990. Lubec G, Rosenthal GA, editors. Toxicity of D-proline. Amino Acids: Chem., Biol. Med. [Pap. Int. Congr. Amino Acid Res. 1989].
21. Cf. Chem Abstr 116:104936, 1992. Leiden: ESCOM. pp. 1164-1171.
22. Ercal N, Luo X, Matthews RH, Armstrong DW. 1996. In vitro study of the metabolic effects of D-amino acids. Chirality 8:24-29.
23. Garcia H, Lijinsky W. 1973. Studies of the tumorigenic effect in feeding of nitrosamino acids and of low doses of amines and nitrite to rats. Z Krebsforsch 79:141-144.
24. Greenblatt M, Lijinsky W. 1972. Failure to induce tumors in swiss mice after concurrent administration of amino acids and sodium nitrite. J Natl Cancer Inst 48:1389-1392.
25. Mirvish SS, Bulay O, Runge RG, Patil K. 1980. Study of the carcinogenicity of large doses of dimethylnitramine, N-nitroso-L-proline, and sodium nitrite administered in drinking water to rats. J Natl Cancer Inst 64:1435-1442.
26. Nixon JE, Wales JH, Scanlan RA, Bills DD, Sinnhuber RO. 1976. Null carcinogenic effect of large doses of nitrosoproline and nitrosohydroxyproline in wistar rats. Food Cosmet Toxicol 14:133-135.
27. Nagasawa HT, Fraser MD, Yuzon DL. 1973. New method for nitrosation of proline and related sec-a-amino acids to N-nitrosamino acids with possible oncogenic activity. J Med Chem 16:583-585.
28. Hecht SS, Abbaspour A, Hoffman DA. 1988. A study of tobacco carcinogenesis XLII. Bioassay in A/J mice of some structural analogs of tobacco-specific nitrosamines. Cancer Lett 42:141-145.
29. Lijinsky W, Reuber MD. 2001. In Bartsch H, O'Neill IK, Castegnaro M, Okada M, editors. Transnitrosation by nitrosamines in vivo. N-Nitroso compounds: Occurrence and biological effects. Lyon: International Agency for Research on Cancer (IARC Scientific Publications No. 41). pp. 625-631.
30. Hubbard WK. 1997. International Conference on Harmonisation; Guidance on Impurities: Residual Solvents. Fed Regist 62:67377-67388.
31. Lundell A, Marijianowski M, Keefer LK, Davies KM, Saavedra JE, Hanson S. Boundary layer infusion of a fast-acting nitric oxide donor, PROLI/NO, reduces neointima formation at ePTFE arterial vascular graft anastomoses in non-human primates. (Unpublished data)